Clinical Trial Update: RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL. [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing reduced-intensity conditioning with thiotepa plus busulfan/fludarabine/cytarabine in allogeneic HSCT for relapsed or refractory periph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• BUSULFAN (Busulfan)
• CYTARABINE (CYTARABINE)
• Fludarabine (Fludarabine)
• THIOTEPA (THIOTEPA)

Snippet

Sponsor: Xianmin Song, MD | Conditions: Peripheral T Cell Lymphoma | Phase 2 | Status: RECRUITING